← Back to Screener
Onconetix, Inc. Common Stock (ONCO)
Price$1.09
Growth ScoreF
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-112.61%
Price vs S&P 500 (4W)-83.02%
VGM Score9.41
Market Capitalization$1.31M
All Metrics
Book Value / Share (Quarterly)$42.64
P/TBV (Annual)0.54x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-35.57
Price vs S&P 500 (YTD)-109.93%
Gross Margin (TTM)79.63%
Net Profit Margin (TTM)-1319.55%
EPS (TTM)$-219.70
10-Day Avg Trading Volume2.42M
EPS Excl Extra (TTM)$-219.70
EPS (Annual)$-748.39
ROI (Annual)-89.00%
Gross Margin (Annual)77.62%
Cash / Share (Quarterly)$13.49
Revenue Growth QoQ (YoY)-78.88%
ROA (Last FY)-56.29%
Revenue Growth TTM (YoY)-61.81%
EBITD / Share (TTM)$-357.45
ROE (5Y Avg)-211.86%
Operating Margin (TTM)-2868.99%
Cash Flow / Share (Annual)$-310.20
P/B Ratio0.11x
P/B Ratio (Quarterly)0.09x
Net Income / Employee (Annual)$-7,016,200
EV / Revenue (TTM)-2.94x
Net Interest Coverage (TTM)-3.72x
ROA (TTM)-49.40%
EPS Incl Extra (Annual)$-748.39
Current Ratio (Annual)0.66x
Quick Ratio (Quarterly)1.24x
3-Month Avg Trading Volume0.83M
52-Week Price Return-99.66%
Revenue / Employee (TTM)$367,600
Tangible BV / Share (Quarterly)$69.53
P/S Ratio (Annual)1.60x
Asset Turnover (Annual)0.03x
52-Week High$382.50
EPS Excl Extra (Annual)$-748.39
26-Week Price Return-99.03%
Quick Ratio (Annual)0.61x
13-Week Price Return-96.49%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.41x
Enterprise Value$-2.16M
Asset Turnover (TTM)0.04x
Revenue / Employee (Annual)$407,700
Pretax Margin (Annual)-1720.91%
Cash / Share (Annual)$167.33
3-Month Return Std Dev217.37%
Net Income / Employee (TTM)$-4,850,700
ROE (Last FY)-89.00%
Net Interest Coverage (Annual)0.10x
EPS Basic Excl Extra (Annual)$-748.39
Receivables Turnover (TTM)24.50x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-219.70
ROI (TTM)-83.66%
P/S Ratio (TTM)1.78x
Revenue / Share (Annual)$43.49
Tangible BV / Share (Annual)$3482.08
Price vs S&P 500 (52W)-127.82%
Year-to-Date Return-98.54%
5-Day Price Return-2.56%
EPS Normalized (Annual)$-748.39
ROA (5Y Avg)-93.87%
Net Profit Margin (Annual)-1720.98%
Month-to-Date Return-5.00%
EBITD / Share (Annual)$-1249.21
Operating Margin (Annual)-2874.50%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-149.88%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-219.70
P/TBV (Quarterly)0.54x
P/B Ratio (Annual)0.15x
Inventory Turnover (TTM)1.02x
Pretax Margin (TTM)-1319.48%
Book Value / Share (Annual)$505.33
Price vs S&P 500 (13W)-107.16%
Beta2.72x
Revenue / Share (TTM)$11.70
ROE (TTM)-104.19%
52-Week Low$0.91
gGradeF
mGradeF
vgmGradeF
Show chart for
Analyst Recommendations
Feb 2024
Mar 2024
Apr 2024
May 2024
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ONCOOnconetix, Inc. Common Stock | — | F | F | $1.09 |
| LLYEli Lilly & Co. | D | B | B | $1078.78 |
| JNJJohnson & Johnson | C | C | C | $223.24 |
| ABBVABBVIE INC. | D | C | C | $217.13 |
| MRKMerck & Co., Inc. | C | C | C | $114.70 |
| AZNAstraZeneca PLC | D | B | C | $176.28 |
| NVSNovartis AG | C | C | C | $143.66 |
| NVONovo-Nordisk A/S | B | B | B | $42.00 |
| ABTAbbott Laboratories | C | C | D | $86.99 |
| PFEPfizer Inc. | B | C | C | $25.34 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $32.83 |
About
Onconetix Inc is a commercial-stage biotechnology company specializing in men's health and oncology solutions. The company markets Entadfi, an FDA-approved once-daily oral therapy for benign prostatic hyperplasia. Beyond its flagship product, Onconetix is developing a pipeline of oncology-focused therapeutics, diagnostics, and clinician services.